Serge  Saxonov net worth and biography

Serge Saxonov Biography and Net Worth

CEO of 10x Genomics
Serge Saxonov co-founded 10x Genomics in 2012. As the CEO, he defined the 10x vision and strategy, contributed to core inventions, and has led the company since inception. Prior to 10x Genomics, Serge was Vice President of Applications at QuantaLife, where he built products and defined the company’s growth areas. Serge was the first employee at 23andMe, where he served as Founding Architect and Director of R&D. There he defined the initial concept of the product, built out the core technology, and drove strategy and execution of R&D functions. Serge received a Ph.D. in biomedical informatics from Stanford University and an A.B. in applied mathematics from Harvard College.

What is Serge Saxonov's net worth?

The estimated net worth of Serge Saxonov is at least $8.06 million as of February 24th, 2025. Dr. Saxonov owns 879,482 shares of 10x Genomics stock worth more than $8,056,055 as of March 29th. This net worth approximation does not reflect any other assets that Dr. Saxonov may own. Additionally, Dr. Saxonov receives a salary of $925,050.00 as CEO at 10x Genomics. Learn More about Serge Saxonov's net worth.

How old is Serge Saxonov?

Dr. Saxonov is currently 47 years old. There are 2 older executives and no younger executives at 10x Genomics. Learn More on Serge Saxonov's age.

What is Serge Saxonov's salary?

As the CEO of 10x Genomics, Inc., Dr. Saxonov earns $925,050.00 per year. Learn More on Serge Saxonov's salary.

How do I contact Serge Saxonov?

The corporate mailing address for Dr. Saxonov and other 10x Genomics executives is 6230 STONERIDGE MALL ROAD, PLEASANTON CA, 94588. 10x Genomics can also be reached via phone at 925-401-7300 and via email at investors@10xgenomics.com. Learn More on Serge Saxonov's contact information.

Has Serge Saxonov been buying or selling shares of 10x Genomics?

During the last ninety days, Serge Saxonov has sold $56,368.44 in shares of 10x Genomics stock. Most recently, Serge Saxonov sold 5,092 shares of the business's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $11.07, for a transaction totalling $56,368.44. Following the completion of the sale, the chief executive officer now directly owns 879,482 shares of the company's stock, valued at $9,735,865.74. Learn More on Serge Saxonov's trading history.

Who are 10x Genomics' active insiders?

10x Genomics' insider roster includes Bradford Crutchfield (Insider), Benjamin Hindson (Insider), Sridhar Kosaraju (Director), Mathai Mammen (Director), Alan Mateo (Director), Justin McAnear (CFO), Serge Saxonov (CEO), John Stuelpnagel (Director), and James Wilbur (Insider). Learn More on 10x Genomics' active insiders.

Are insiders buying or selling shares of 10x Genomics?

During the last year, 10x Genomics insiders bought shares 1 times. They purchased a total of 40,000 shares worth more than $445,600.00. During the last year, insiders at the sold shares 8 times. They sold a total of 35,626 shares worth more than $712,955.88. The most recent insider tranaction occured on February, 24th when insider Benjamin J Hindson sold 4,573 shares worth more than $50,623.11. Insiders at 10x Genomics own 10.0% of the company. Learn More about insider trades at 10x Genomics.

Information on this page was last updated on 2/24/2025.

Serge Saxonov Insider Trading History at 10x Genomics

Serge Saxonov Buying and Selling Activity at 10x Genomics

This chart shows Serge Saxonov's buying and selling at 10x Genomics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$56ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$2M$0$2MTotal Insider BuyingTotal Insider Selling

10x Genomics Company Overview

10x Genomics logo
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Read More

Today's Range

Now: $9.16
Low: $8.92
High: $9.47

50 Day Range

MA: $12.12
Low: $9.16
High: $16.31

2 Week Range

Now: $9.16
Low: $8.92
High: $37.86

Volume

2,665,243 shs

Average Volume

2,075,825 shs

Market Capitalization

$1.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.93